

REMARKS:

This is in response to the Notice of Non-compliant Amendment mailed March 27, 2007, indicating that two of the claim identifiers were incorrect. By way of this response, the claim identifiers have been changed to adequately represents the state of the claim in which it identifies. No new matter has been added.

Claims 14-33 are pending in the application. By way of this amendment, claims 17, 26-28 and 31-33 have been cancelled and claims 34-41 have been added. Support for claims 34-40 can be found throughout the specification and original claims, in particular at pages 5-9. No new matter has been added.

In the Office Action, the abstract of the disclosure has been objected to for containing the term "novel." The abstract and the first paragraph on page 1 of the specification have been amended to delete the term "novel." In view of the foregoing, it is respectfully requested that the objection be reconsidered and withdrawn.

In the Office Action, Claims 14-33 have been objected to because of several informalities. Claims 14-16, 18-25, 27, 29-30 have been amended in order to better describe the invention and overcome the objections. In view of the foregoing amendments, it is respectfully requested that the objections be reconsidered and withdrawn.

In the Office Action, Claims 14-24 and 26-33 were rejected under 35 U.S.C. §112, first paragraph as allegedly being indefinite for merely reciting a use without any active, positive steps for determining how this use is actually practiced. Claims 14-24 and 26-33 were also rejected under 35 U.S.C. § 101 because the claims recite a use without setting forth any steps involved in the process, results in an improper definition of a

process under 35 U.S.C. § 101. Finally, Claims 14-33 were rejected under 35 U.S.C. § 112, second paragraph as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 14 has been amended so as to be recite a pharmaceutical composition and new claims 34-39 have been added directed to a method of treating schizophrenia using the pharmaceutical composition of Claim 14. In addition, the Claims have been amended so as to more distinctly describe the subject of which is being claimed. In view of the foregoing Claim amendments, it is respectfully asserted that the rejections under 35 U.S.C. § 101 and 35 U.S.C. § 112, first and second paragraphs be reconsidered and withdrawn.


Turning now to the rejection of the Claims on the merits. Claim 25 has been rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Song (Chinese Patent Abstract, (CN 117264)). In making the rejection, the Examiner states that Song teaches a medicine in the form of a honey pill or capsule comprising ginseng and sulpride (which is a medicine for treating schizophrenia) for treating schizophrenia. (See Office Action page 13). Claim 25 has been amended so as to exclude pill and capsule form. Therefore, since Song only teaches a honey pill and/or capsule, Song does not teach each and every element of the Claim 25. In view of the foregoing, it is respectfully requested that the rejection of Claim 25 be reconsidered and withdrawn.

Finally, the Examiner has stated that the references cited in the IDS that have a line through it were not considered since no English translation was provided. Attached herewith is a copy of EP 0 599 307 B1 in which the claims are translated into English. In addition, it is noted although DE 33 38 995 that corresponding US applications to DE 33 38 995 are US 4,892,882 and US 4,571,407. It is respectfully requested that these references now be considered.

Accordingly, in view of the forgoing amendment and accompanying remarks, it is respectfully submitted all claims pending herein are in condition for allowance. Please contact the undersigned attorney should there be any questions.

Favorable consideration of the application as amended is respectfully requested and early favorable action is earnestly solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'L. G. Lenna', written over a horizontal line.

Leo G. Lenna
Registration No.42,796
Attorney for Applicant(s)

DILWORTH & BARRESE LLP.
333 Earle Ovington Blvd.
Uniondale, NY 11553
Telephone: (516) 228-8484
FAX: (516) 228-8516